ÂÜÀòÊÓÆµ

Artificial intelligence • Defense tech • Fintech • Health, Wellness & Biotech • Insurance tech • Manufacturing • Seed funding • Semiconductors and 5G • Startups • Transportation & Logistics • Venture

The Week’s 10 Biggest Funding Rounds: SiFive Leads With $400M For Custom Chip Designs As Aviation, Biotech And Defense Startups Also Raise Big

Illustration of gardener holding a rake. Venture

Want to keep track of the largest startup funding deals in 2026 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The ÂÜÀòÊÓÆµ Megadeals Board.

This is a weekly feature that runs down the week’s top 10 announced funding rounds in the U.S. Check out last week’s biggest funding deal roundup here.

While no billion-dollar rounds led this week’s list, we nonetheless saw a variety of startups in industries ranging from semiconductors to aerospace to biotech raise sizable rounds. The week’s biggest deal was $400 million for SiFive, a semiconductor startup challenging incumbent with chip designs built on an open rather than proprietary standard.

1. , $400M, semiconductors: San Mateo, California-based semiconductor startup SiFive raised a $400 million Series G round led by . SiFive makes the blueprints used by companies such as to develop their own internal chip designs, on an open standard called RISC-V. CEO Reuters he expects the raise to be SiFive’s last funding round before an IPO, though didn’t say when an offering would take place.

2. , $200M, aviation: Hermeus, an El Segundo, California-based startup developing autonomous military aircraft, raised $200 million in equity in a -led round. The company, which is developing what it says will be the fastest unmanned defense aircraft, also raised $150 million in debt as part of the round, which pushes its valuation to $1 billion. Other investors in the deal include , and

3. $137M, biotechnology: San Diego-based Sidewinder, a biotech startup developing cancer drugs to target difficult-to-treat tumors, raised a $137 million Series B led by and . The company is developing next-generation cancer drugs called antibody-drug conjugates, or ADCs, which are designed to act like “guided missiles� by using engineered antibodies to deliver toxic payloads directly into tumor cells. The company said its new funding will be used to push its lead drug candidates into clinical trials.

4. , $125M, AI infrastructure: Palo Alto, California-based Aria Networks raised $125 million in a -led Series A funding round. The company develops an AI-driven networking platform that monitors, analyzes and optimizes data center performance.

5. , $111.7M, aerospace: Starfish Space, a Seattle-based startup developing and manufacturing autonomous space vehicles that perform in-orbit, satellite servicing missions, raised $111.7 million. The Series B round was led by , and . Starfish’s spacecraft dock to satellites already in orbit to service and reposition them. They can also remove defunct satellites and debris from space.

6. (tied) , $100M, biotechnology: Cambridge, Massachusetts-based Stipple Bio raised a $100 million Series A round to advance its precision cancer therapies. The round was led by , and . Stipple aims to develop highly targeted cancer treatments that selectively attack cancer cells while minimizing damage to healthy tissue.

6. (tied) , $100M, health insurance: led the $100 million Series E for Chapter, a New York-based startup offering a Medicare navigation platform that provides advisory services for seniors seeking health coverage. Other investors include ​​, and 1.

8. , $85M, fintech: Modus, a Philadelphia-based startup, raised $85 million in a -led seed and Series A round. The startup describes itself as a tech‑enabled audit platform that acquires CPA firms and equips them with AI‑driven audit tools to deliver higher‑quality audits. and also participated in the deal.

9. , $80M, medical devices: and led the $80 million Series C for Menlo Park, California-based Endovascular Engineering, also called E2, which has developed a device called Hēlo for the treatment of venous thromboembolism, or VTE. The company secured clearance for Hēlo in December.

10. , $80M, biotechnology: Boston-based Life Sciences, which aims to develop drugs to promote longevity and find treatments for age-related diseases, says it raised $80 million in Series D funding. The company says it will use the funding to advance human trials of its cellular rejuvenation therapy, called ER-100, which aims to make older, damaged cells act younger again. Investors in the round were not disclosed. The company has previously been backed by , , , and.

Methodology

We tracked the largest announced rounds in the ÂÜÀòÊÓÆµ database that were raised by U.S.-based companies for the period of April 4-10. Although most announced rounds are represented in the database, there could be a small time lag as some rounds are reported late in the week.

Illustration:


  1. 8VC is an investor in ÂÜÀòÊÓÆµ. They have no say in our editorial process. For more, head here.↩

Stay up to date with recent funding rounds, acquisitions, and more with the ÂÜÀòÊÓÆµ Daily.

67.1K Followers

CTA

Copy link